{"doc_id": "PMID-8810619.txt", "sent_id": "", "tokens": ["Tyloxapol", "inhibits", "NF-kappa", "B", "and", "cytokine", "release", ",", "scavenges", "HOCI", ",", "and", "reduces", "viscosity", "of", "cystic", "fibrosis", "sputum", "."], "sentence": "Tyloxapol inhibits NF-kappa B and cytokine release , scavenges HOCI , and reduces viscosity of cystic fibrosis sputum .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-8810619.txt", "sent_id": "", "tokens": ["Cystic", "fibrosis", "(", "CF", ")", "patients", "develop", "progressive", "cytokine", "-", "mediated", "inflammatory", "lung", "disease", ",", "with", "abundant", "production", "of", "thick", ",", "tenacious", ",", "protease", "-", "and", "oxidant-rich", "purulent", "airway", "secretions", "that", "are", "difficult", "to", "clear", "even", "with", "physiotherapy", "."], "sentence": "Cystic fibrosis ( CF ) patients develop progressive cytokine - mediated inflammatory lung disease , with abundant production of thick , tenacious , protease - and oxidant-rich purulent airway secretions that are difficult to clear even with physiotherapy .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-8810619.txt", "sent_id": "", "tokens": ["In", "the", "search", "for", "a", "potential", "treatment", ",", "we", "have", "tested", "tyloxapol", ",", "an", "alkylaryl", "polyether", "alcohol", "polymer", "detergent", "previously", "used", "as", "a", "mucolytic", "agent", "in", "adult", "chronic", "bronchitis", "."], "sentence": "In the search for a potential treatment , we have tested tyloxapol , an alkylaryl polyether alcohol polymer detergent previously used as a mucolytic agent in adult chronic bronchitis .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-8810619.txt", "sent_id": "S4", "tokens": ["Tyloxapol", "inhibits", "activation", "of", "the", "transcription", "factor", "nuclear", "factor-kappa", "B", "(", "NK-kappa", "B", ")", ",", "reduces", "resting", "secretion", "of", "the", "cytokine", "interleukin-8", "(", "IL-8", ")", "in", "cultured", "human", "monocytes", ",", "and", "inhibits", "lipopolysaccharide", "(", "LPS", ")", "-", "stimulated", "release", "of", "tumor", "necrosis", "factor-alpha", "(", "TNF-alpha", ")", ",", "IL-1", "beta", ",", "IL-6", ",", "IL-8", ",", "granulocyte-macrophage", "colony-stimulating", "factor", "(", "GM-CSF", ")", ",", "and", "the", "eiconsanoids", "thromboxane", "A2", "and", "leukotriene", "B4", "(", "LTB4", ")", "."], "sentence": "Tyloxapol inhibits activation of the transcription factor nuclear factor-kappa B ( NK-kappa B ) , reduces resting secretion of the cytokine interleukin-8 ( IL-8 ) in cultured human monocytes , and inhibits lipopolysaccharide ( LPS ) - stimulated release of tumor necrosis factor-alpha ( TNF-alpha ) , IL-1 beta , IL-6 , IL-8 , granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , and the eiconsanoids thromboxane A2 and leukotriene B4 ( LTB4 ) .", "event_mentions": [], "entity_mentions": [{"id": "T1", "text": "interleukin-8", "entity_type": "Protein", "start": 21, "end": 21}, {"id": "T2", "text": "IL-8", "entity_type": "Protein", "start": 23, "end": 23}, {"id": "T3", "text": "tumor necrosis factor-alpha", "entity_type": "Protein", "start": 40, "end": 42}, {"id": "T4", "text": "TNF-alpha", "entity_type": "Protein", "start": 44, "end": 44}, {"id": "T5", "text": "IL-1 beta", "entity_type": "Protein", "start": 47, "end": 48}, {"id": "T6", "text": "IL-6", "entity_type": "Protein", "start": 50, "end": 50}, {"id": "T7", "text": "IL-8", "entity_type": "Protein", "start": 52, "end": 52}, {"id": "T8", "text": "granulocyte-macrophage colony-stimulating factor", "entity_type": "Protein", "start": 54, "end": 56}, {"id": "T9", "text": "GM-CSF", "entity_type": "Protein", "start": 58, "end": 58}]}
{"doc_id": "PMID-8810619.txt", "sent_id": "", "tokens": ["We", "have", "previously", "shown", "that", "tyloxapol", "is", "a", "potent", "antioxidant", "for", "hydroxyl", "radicals", "(", "OH", ")", "."], "sentence": "We have previously shown that tyloxapol is a potent antioxidant for hydroxyl radicals ( OH ) .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-8810619.txt", "sent_id": "", "tokens": ["Tyloxapol", "(", "0.05", "to", "0.1", "%", "wt", "/", "vol", ")", "effectively", "scavenges", "the", "oxidant", "hypochlorous", "acid", "(", "HOCl", ";", "1", "to", "7.5", "mM", ")", "in", "vitro", ",", "and", "protects", "from", "HOCl", "-", "mediated", "lung", "injury", "in", "rats", "."], "sentence": "Tyloxapol ( 0.05 to 0.1 % wt / vol ) effectively scavenges the oxidant hypochlorous acid ( HOCl ; 1 to 7.5 mM ) in vitro , and protects from HOCl - mediated lung injury in rats .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-8810619.txt", "sent_id": "", "tokens": ["Tyloxapol", "also", "reduces", "the", "viscosity", "of", "CF", "sputum", "(", "from", "463", "+/-", "133", "to", "128", "+/-", "52", "centipoise", ")", "."], "sentence": "Tyloxapol also reduces the viscosity of CF sputum ( from 463 +/- 133 to 128 +/- 52 centipoise ) .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-8810619.txt", "sent_id": "", "tokens": ["We", "conclude", "that", "tyloxapol", "is", "potentially", "useful", "as", "a", "new", "antiinflammatory", "therapy", "for", "CF", "lung", "disease", ",", "and", "could", "possibly", "promote", "clearance", "of", "secretions", "in", "the", "CF", "airway", "."], "sentence": "We conclude that tyloxapol is potentially useful as a new antiinflammatory therapy for CF lung disease , and could possibly promote clearance of secretions in the CF airway .", "event_mentions": [], "entity_mentions": []}
